Journal of Medicinal Chemistry p. 5623 - 5642 (2018)
Update date:2022-08-15
Topics:
Wang, Feng
Jeon, Kyu Ok
Salovich, James M.
Macdonald, Jonathan D.
Alvarado, Joseph
Gogliotti, Rocco D.
Phan, Jason
Olejniczak, Edward T.
Sun, Qi
Wang, Shidong
Camper, Demarco
Yuh, Joannes P.
Shaw, J. Grace
Sai, Jiqing
Rossanese, Olivia W.
Tansey, William P.
Stauffer, Shaun R.
Fesik, Stephen W.
WDR5 is a chromatin-regulatory scaffold protein overexpressed in various cancers and a potential epigenetic drug target for the treatment of mixed-lineage leukemia. Here, we describe the discovery of potent and selective WDR5-WIN-site inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified several chemically distinct hit series that bind to the WIN site within WDR5. Members of a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole fragment class were expanded using a structure-based design approach to arrive at lead compounds with dissociation constants <10 nM and micromolar cellular activity against an AML-leukemia cell line. These compounds represent starting points for the discovery of clinically useful WDR5 inhibitors for the treatment of cancer.
View MoreContact:+49-4101-3053-0
Address:Waldhofstrasse 14 ,25474 Ellerbek Germany
Anhui Sholon New Material Technology Co., Ltd.
website:http://www.sholonchem.com
Contact:+86-550-5261666
Address:4/F Block B, Beijing Chemical Building.No.520 Tianrun Road ,Science & Education Town Wujin District, Changzhou City Jiangsu Province
Contact:+31-24-3886056
Address:Binderskampweg 29 Unit 36
Hebei Fulong Import & Export Co., Ltd.
Contact:86-311-87795661
Address:15A19 Zhongyuan Building,368 Youyi North Street,Shijiazhuang 050070,China
Contact:+86-579-85206992
Address:No 451 chouzhou north road ,room 1106 int'l business center , yiwu ,china
Doi:10.1007/BF00763697
(1986)Doi:10.1080/00397919608003762
(1996)Doi:10.1016/j.tet.2012.09.087
(2012)Doi:10.1021/acscatal.8b00923
(2018)Doi:10.1248/cpb.34.1950
(1986)Doi:10.1016/j.tet.2008.08.010
(2008)